Revenue and Profit - The company's revenue for Q3 2022 was ¥69,587,170.73, representing a year-on-year increase of 0.98% and a cumulative revenue of ¥213,601,944.93 for the year-to-date, which is a 24.80% increase compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2022 was -¥3,544,142.80, a significant decline of 658.09% year-on-year, with a year-to-date net profit of -¥15,145,520.13, reflecting a decrease of 1,049.40%[3]. - Total operating revenue for Q3 2022 reached CNY 213.60 million, an increase of 24.8% compared to CNY 171.15 million in the same period last year[24]. - Net loss attributable to shareholders of the parent company was CNY 15.15 million, compared to a profit of CNY 1.60 million in Q3 2021, indicating a significant decline[25]. - The company reported a comprehensive loss of CNY 19.66 million for Q3 2022, compared to a loss of CNY 1.15 million in the same quarter last year[26]. - Basic and diluted earnings per share for Q3 2022 were both CNY -0.0135, a decrease from CNY 0.0014 in Q3 2021[26]. Assets and Liabilities - The company's total assets decreased by 6.36% from the end of the previous year, amounting to ¥591,486,663.60[4]. - The company reported a total liability of CNY 201.51 million, down from CNY 221.38 million year-over-year, reflecting a decrease of 9.0%[22]. - The company's total equity decreased to CNY 389.98 million from CNY 410.25 million, a decline of 4.9% year-over-year[23]. - The company’s total liabilities and equity amounted to CNY 591.49 million, down from CNY 631.63 million year-over-year, reflecting a decrease of 6.3%[23]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥29,006,195.12, down 60.78% compared to the same period last year[12]. - The net cash flow from operating activities for Q3 2022 was ¥29,006,195.12, a decrease of 60.8% compared to ¥73,951,942.16 in Q3 2021[29]. - Total cash inflow from operating activities was ¥269,913,970.80, while cash outflow was ¥240,907,775.68, resulting in a net cash inflow of ¥29,006,195.12[30]. - The net cash flow from investing activities was -¥46,358,181.76, compared to -¥7,836,278.71 in the same period last year, indicating increased investment outflows[30]. - Cash inflow from financing activities was ¥43,598,241.30, with a net cash flow of ¥42,267,045.83 after outflows[30]. - The ending balance of cash and cash equivalents was ¥210,968,632.37, up from ¥175,554,042.85 at the end of Q3 2021[30]. - The company received tax refunds amounting to ¥4,673,833.71 during the quarter[29]. - Cash received from other operating activities totaled ¥25,144,844.93, a decrease from ¥47,713,645.56 in the previous year[29]. - The company paid ¥108,291,741.68 for goods and services, significantly higher than ¥38,598,425.05 in Q3 2021[29]. - The company reported a cash outflow of ¥97,933,263.95 for other operating activities, compared to ¥64,510,204.20 in the same period last year[29]. - The company’s cash flow from financing activities was positively impacted by a loan of ¥10,000,000.00 received during the quarter[30]. Inventory and Borrowings - The company reported a significant increase in inventory, which rose by 61.90% to ¥121,717,211.16, attributed to increased raw material reserves[9]. - The company’s short-term borrowings increased to ¥10,000,000.00, marking a 100% increase compared to the previous year[9]. - Inventory increased from ¥75,178,330.47 to ¥121,717,211.16 during the same period[21]. Research and Development - The company’s research and development expenses increased by 31.24% to ¥8,877,358.50, reflecting a commitment to innovation[9]. - Research and development expenses for Q3 2022 were CNY 11.05 million, an increase of 25.0% from CNY 8.84 million in the previous year[25]. - The company has increased its development expenditure from ¥6,764,150.94 to ¥8,877,358.50[21]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 85,071[14]. - The largest shareholder, Wu Jianlong, holds 18.15% of the shares, totaling 203,219,417 shares, with 154,000,000 shares pledged[14]. Corporate Actions - The company has ongoing plans for a private placement of shares, with relevant proposals approved by the board and shareholders[16]. - The company is in the process of responding to inquiries from the Shenzhen Stock Exchange regarding its application for a specific stock issuance[17]. - The company has settled a loan repayment, resolving related litigation[18].

浙江向日葵大健康科技股份有限公司 2022 年半年度报告全文 浙江向日葵大健康科技股份有限公司 2022 年半年度报告 2022 年 08 月 1 浙江向日葵大健康科技股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人曹阳、主管会计工作负责人潘卫标及会计机构负责人(会计主 管人员)吴丹琳声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及的公司未来发展战略、经营计划等前瞻性陈述，不构成公司 对投资者的实质承诺，敬请投资者注意投资风险。 公司在本报告第三节"管理层讨论与分析"中"十、公司面临的风险和 应对措施"部分，详细描述了公司经营中可能存在的风险，敬请投资者关注 相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 重要提示、目录和释义 | | 1 | | --- | --- | --- | | 第二节 公司简介和主要财务指标 | | 7 ...

浙江向日葵大健康科技股份有限公司 2022 年第一季度报告全文 证券代码：300111 证券简称：向日葵 公告编号：2022-022 浙江向日葵大健康科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信 息的真实、准确、完整。 3.第一季度报告是否经过审计 浙江向日葵大健康科技股份有限公司 2022 年第一季度报告全文 (二)非经常性损益项目和金额 √ 适用 □ 不适用 单位：元 | 项目 | 本报告期金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部分） | -5,982.91 | | | 计入当期损益的政府补助（与公司正常经营业务密切相关，符 合国家政策规定、按照一定标准定额或定量持续享受的政府补 助除外 ...

Financial Performance - The company's operating revenue for 2021 was approximately ¥297.29 million, representing a 3.60% increase compared to ¥286.96 million in 2020[20]. - The net profit attributable to shareholders decreased by 4.39% to ¥53.42 million in 2021 from ¥55.87 million in 2020[20]. - The net profit after deducting non-recurring gains and losses dropped significantly by 77.73% to ¥3.81 million in 2021 from ¥17.10 million in 2020[20]. - The net cash flow from operating activities increased by 86.20% to ¥99.27 million in 2021, compared to ¥53.31 million in 2020[20]. - The total assets at the end of 2021 were approximately ¥631.63 million, an increase of 11.90% from ¥564.44 million at the end of 2020[20]. - The net assets attributable to shareholders rose by 91.06% to ¥286.90 million at the end of 2021, compared to ¥150.17 million at the end of 2020[20]. - The company reported a basic earnings per share of ¥0.05 for 2021, unchanged from 2020[20]. - The weighted average return on equity decreased to 24.44% in 2021 from 55.73% in 2020, a decline of 31.29%[20]. - The company reported a total revenue of CNY 297.29 million for 2021, an increase of 3.60% compared to the previous year[46]. - The cost of goods sold was CNY 187.59 million, up 1.66% year-over-year[46]. - Sales expenses rose to CNY 54.02 million, a significant increase of 23.34% due to enhanced marketing efforts[46]. - Research and development expenses increased by 8.21% to CNY 12.27 million[46]. - The company faced a significant decline in overseas sales of clarithromycin raw materials due to the impact of the COVID-19 pandemic[47]. - The company successfully won a bid for clarithromycin tablets in the third batch of national centralized drug procurement, leading to increased sales volume[48]. - The procurement of Lercanidipine dispersible tablets was set at 280,000 pieces for one year, enhancing market share and brand recognition[48]. - The company reported a 60,361.03% decrease in financial expenses, attributed to the absence of loans and reduced interest expenses[46]. Business Operations - The company focuses on pharmaceutical products, particularly in the fields of anti-infection and cardiovascular diseases, with a leading position in the domestic clarithromycin raw material market[32]. - The company's revenue is primarily derived from raw materials and formulations, with clarithromycin raw materials being a major component sold to domestic and international manufacturers[33]. - The company has obtained 18 drug production licenses and holds a total of 36 patents, including 3 invention patents and 33 utility model patents, enhancing its technological capabilities[32]. - The clarithromycin tablets and the Lercanidipine dispersible tablets have been included in the National Essential Medicines List and the National Medical Insurance Directory, ensuring stable market demand[32]. - The company has developed a core technology in the production of anti-infection and antihypertensive drugs over years of development[32]. - The company employs a "sales-driven procurement" model, ensuring that production plans align with sales forecasts and inventory levels[36]. - The production process adheres strictly to national GMP standards, with quality supervision throughout the entire production cycle[37]. - The sales model includes direct sales and export through trading companies, adapting to different international markets[40]. - The formulation sales model consists of bidding and distributor agency modes, with key products like Lercanidipine dispersible tablets primarily sold through bidding[41]. - The company aims to continuously improve product quality and expand market share through ongoing research and development efforts[32]. Risk Management - The company emphasizes that forward-looking statements regarding future strategies and operational plans do not constitute a commitment to investors, highlighting potential risks in operations[4]. - The company's management has outlined potential risks in the "Management Discussion and Analysis" section of the report[4]. - The company faces risks from unstable market demand due to the ongoing COVID-19 pandemic, affecting the export of its products[91]. - Regulatory changes in the pharmaceutical industry may increase operational costs and create uncertainties for the company's business[91]. - The company will enhance its management level and improve its control systems across R&D, production, quality, and sales to mitigate operational risks due to policy changes[92]. - The company has not experienced significant product quality incidents but acknowledges potential future quality issues due to raw material procurement and handling processes[93]. - Raw material costs constitute a high proportion of production costs, and the company faces risks of rising costs due to the impact of COVID-19 on raw material prices[93]. - The company plans to strengthen market forecasting and analysis to optimize raw material procurement and inventory management to mitigate cost fluctuations[93]. Corporate Governance - The governance structure of the company complies with relevant laws and regulations, ensuring independent operation from its controlling shareholder[100]. - The company has an independent financial department that adheres to accounting standards and manages its finances without interference from the controlling shareholder[101]. - The company has a complete business system and operates independently in procurement and sales, avoiding competition with its controlling shareholder[100]. - The company has implemented a performance evaluation and incentive system linking management compensation to business performance[98]. - The company has maintained a stable governance structure without any red-chip governance issues[104]. - The company has not reported any requests for a temporary shareholders meeting regarding the restoration of voting rights for preferred shareholders[103]. - The company has not experienced any changes in the positions of directors, supervisors, or senior management during the reporting period[105]. - The company appointed a new independent director, Chen Suqin, on August 16, 2021, following the completion of the term of the previous independent director, Shen Fuxin[105]. - The current board consists of 7 members, including Chairman Cao Yang and General Manager Shi Huaxin, who have extensive backgrounds in finance and management[106]. - The company has a diverse management team with experience in various sectors, including finance, law, and local government[107]. Employee Management - The total number of employees at the end of the reporting period was 294, including 22 at the parent company and 272 at major subsidiaries[126]. - The company has a total of 115 production personnel, 26 sales personnel, 65 technical personnel, 10 financial personnel, and 78 administrative personnel[126]. - The company employs 7 individuals with a postgraduate degree, 64 with a bachelor's degree, 64 with a college diploma, 49 with a high school diploma, and 110 with a junior high school education or below[127]. - The company has established a training system combining external and internal training to enhance employee skills and promote career development[129]. - The company has 24 retired employees for whom it bears costs[126]. Environmental Management - The company’s subsidiary, Zhejiang Beid Pharmaceutical Co., Ltd., emitted 107 tons of COD and 7.49 tons of ammonia nitrogen, both within the regulatory limits[146]. - The company has implemented ISO14001 environmental management system and ISO45001 occupational health and safety management system to enhance management awareness and control risks[148]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[147]. - The company has developed emergency response plans for environmental incidents and has registered them with management authorities[147]. Strategic Initiatives - The company plans to enhance its R&D capabilities and improve product consistency through external collaborations and talent acquisition[89]. - The company aims to strengthen brand management and optimize its marketing system to increase market share[90]. - The company is focused on maintaining transparency and fairness in its related transactions, adhering to market principles[157]. - The company has established a commitment to compensate for any economic losses caused by breaches of its commitments[158]. - The company is actively pursuing cash transactions to facilitate its acquisitions and investments[160]. - The company plans to acquire 60% equity of Zhejiang Beid Pharmaceutical Co., Ltd. through cash transaction[165]. - The company guarantees the independence of its financial department and accounting system, ensuring independent financial decision-making[163]. - The company has committed to maintaining the independence of its operations, assets, and personnel, ensuring no interference from controlling shareholders[164]. - The company has established a sound corporate governance structure, ensuring independent operation of its board and shareholder meetings[163]. Future Outlook - Looking ahead, the company projects a revenue growth of 20% for 2022, targeting 1.44 billion yuan in total revenue[178]. - The company is actively developing new products, with plans to launch three innovative health supplements in the next quarter[179]. - Zhejiang Sunflower is pursuing market expansion strategies, including entering two new provinces in China by mid-2022[180]. - The company is focused on enhancing its R&D capabilities, with an investment of 100 million yuan planned for the next fiscal year[177].

Financial Performance - The company's revenue for Q3 2021 was ¥68,913,672.94, representing a 41.66% increase compared to the same period last year[3]. - Year-to-date revenue as of Q3 2021 was ¥171,149,091.46, showing a decline of 15.41% compared to the previous year[3]. - Total operating revenue for Q3 2021 was ¥171,149,091.46, a decrease of 15.4% compared to ¥202,331,603.19 in the same period last year[28]. - Net profit for Q3 2021 was a loss of ¥1,113,668.82, compared to a profit of ¥31,212,100.56 in Q3 2020[30]. - The net profit attributable to shareholders decreased by 74.92% to ¥635,051.81, while the net profit excluding non-recurring items dropped by 91.01% to ¥876,542.04[3]. - The company reported a total comprehensive income of -¥1,150,267.77 for Q3 2021, compared to ¥31,165,554.36 in the same quarter last year[31]. Assets and Liabilities - The company's total assets at the end of Q3 2021 were ¥479,604,630.88, a decrease of 15.03% from the previous year[4]. - The company's total liabilities amounted to ¥209,695,089.62, a decrease from ¥293,385,022.11 in the previous period[27]. - The company's current assets decreased to CNY 304,742,559.50 from CNY 383,372,492.39, reflecting a reduction of about 20.55%[25]. - The company's fixed assets decreased to CNY 132,553,522.67 from CNY 143,025,590.58, a reduction of about 7.34%[25]. - The company’s total liabilities and equity amounted to ¥479,604,630.88, down from ¥564,444,831.14 in the previous period[27]. Cash Flow - Cash flow from operating activities for the year-to-date period was ¥73,951,942.16, down 3.34% compared to the previous year[3]. - Operating cash inflow for the current period was ¥212,527,883.52, a decrease of 14.6% from ¥248,929,782.70 in the previous period[32]. - Net cash flow from operating activities was ¥73,951,942.16, down from ¥76,506,791.29, reflecting a decline of 2.0%[34]. - Cash outflow from investment activities totaled ¥9,939,544.65, compared to ¥296,551,148.06 in the previous period, indicating a significant reduction in investment spending[34]. - Cash flow from financing activities resulted in a net outflow of -¥2,210,397.01, compared to -¥239,572,704.20 in the previous period, indicating improved cash management[34]. - The ending balance of cash and cash equivalents increased to ¥175,554,042.85, up from ¥93,768,870.26, representing an increase of 87.1%[34]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 92,343[14]. - The largest shareholder, Wu Jianlong, holds 18.15% of the shares, totaling 203,219,417 shares, with 154,000,000 shares pledged[14]. - The second largest shareholder, Zhejiang Yingzhun Investment Co., Ltd., holds 1.36% of the shares, totaling 15,279,000 shares[14]. - The top 10 shareholders collectively hold a significant portion of the company's shares, with the largest shareholder holding over 18%[14]. - The total number of shares held by the top 10 unrestricted shareholders is 203,219,417 shares[15]. Legal and Arbitration Matters - The company has ongoing arbitration cases with a total involved amount of approximately 19,853.96 million RMB related to disputes with China Export & Credit Insurance Corporation[18]. - Another arbitration case involves a dispute with Zhongmin New Energy Investment Group, with an amount of 3,850.00 million RMB[18]. - The company is also involved in a dispute with Hainan Haikong Energy, with a claim amount of 1,646.00 million RMB[18]. - The company is currently involved in multiple legal disputes that may impact its financial position and operational strategy moving forward[19][20]. Expenses - The company reported a significant increase in development expenses, which rose by 200% to ¥5,773,584.90 due to increased internal development activities[10]. - Sales expenses increased by 29% to ¥43,030,999.70, attributed to heightened promotional efforts[11]. - Research and development expenses for Q3 2021 were ¥8,839,070.31, an increase of 10.8% from ¥7,973,976.44 in the previous year[28]. Other Financial Metrics - Basic and diluted earnings per share for Q3 2021 were both ¥0.0014, down from ¥0.0210 in Q3 2020[31]. - The company has incurred a total of 3,586,448.04 CNY in overdue payments, with interest and penalties to be settled within one month of the judgment[20].

浙江向日葵大健康科技股份有限公司 2021 年半年度报告全文 浙江向日葵大健康科技股份有限公司 2021 年半年度报告 2021 年 08 月 1 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人曹阳、主管会计工作负责人潘卫标及会计机构负责人(会计主管 人员)吴丹琳声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及的公司未来发展战略、经营计划等前瞻性陈述，不构成公司对 投资者的实质承诺，敬请投资者注意投资风险。 公司在本报告第三节"管理层讨论与分析"中"十、公司面临的风险和应对措 施"部分，详细描述了公司经营中可能存在的风险，敬请投资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 重要提示、目录和释义 2 | | --- | | 第二节 公司简介和主要财务指标 7 | | 第三节 管理层讨论与分析 11 | | 第四节 公司治理 22 | | 第五节 环境与社会责任 ...

2021 年 04 月 1 浙江向日葵大健康科技股份有限公司 2021 年第一季度报告全文 浙江向日葵大健康科技股份有限公司 2021 年第一季度报告 浙江向日葵大健康科技股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曹阳、主管会计工作负责人潘卫标及会计机构负责人(会计主管 人员)吴丹琳声明：保证季度报告中财务报表的真实、准确、完整。 2 浙江向日葵大健康科技股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 51,002,844.05 | 69,969,920.23 | -27.11% | | 归属于上市公司股东的净利润（元） | 5,760,063 ...

Business Performance - The company faced a decline in demand for its products due to the COVID-19 pandemic, particularly in the export of clarithromycin raw materials, with an uncertain duration and impact on overall business performance [5]. - Domestic market sales volume is gradually recovering as the pandemic situation improves, but the demand for antibiotic products has decreased due to heightened self-protection awareness among the public [5]. - The company's operating revenue for 2020 was ¥286,955,031.33, a decrease of 65.70% compared to ¥836,610,095.80 in 2019 [29]. - The net profit attributable to shareholders in 2020 was ¥55,867,920.60, an increase of 148.61% from a loss of ¥114,928,936.87 in 2019 [29]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥17,104,435.21, up 108.45% from a loss of ¥202,458,216.55 in 2019 [29]. - The basic earnings per share for 2020 was ¥0.05, a 150.00% increase from a loss of ¥0.10 in 2019 [29]. - The total assets at the end of 2020 were ¥564,444,831.14, a decrease of 18.67% from ¥694,030,365.47 at the end of 2019 [29]. - The net assets attributable to shareholders increased by 198.27% to ¥150,165,363.71 from ¥50,346,286.12 at the end of 2019 [29]. - The cash flow from operating activities in 2020 was ¥53,314,057.11, a decrease of 8.87% compared to ¥58,504,586.85 in 2019 [29]. - The weighted average return on net assets for 2020 was 55.73%, an increase of 135.01% from -79.28% in 2019 [29]. - The company reported a net profit of ¥32,247,249.66 in Q4 2020, which was the highest quarterly profit for the year [31]. Market Strategy - The company plans to optimize the sales proportion of its market products and actively respond to domestic and international market changes [6]. - The company has shifted its main business focus to the pharmaceutical sector, specifically in the research, production, and sales of anti-infection and antihypertensive drugs, following the divestment of its traditional photovoltaic business as of December 31, 2019 [38]. - The company's revenue is primarily derived from the sales of raw materials and formulations, with clarithromycin raw materials being the main contributor, primarily sold to domestic manufacturers and exported to countries such as India, South Korea, Spain, and Pakistan [38]. - The company employs a "sales-driven procurement" model, maintaining a safety stock and adjusting production plans based on sales forecasts and inventory levels [41]. - The company has developed a complete industrial chain for its main products, including the raw material and formulation of clarithromycin and lacidipine, enhancing its market competitiveness [56]. Financial Management - The company will not distribute cash dividends or issue bonus shares for the reporting period [15]. - The company reported a non-operating income of approximately 38.76 million, with a significant portion attributed to the reversal of impairment provisions for receivables and contract assets [37]. - The company has not experienced any product recalls due to quality issues throughout the year [63]. - The company’s profit distribution policy emphasizes a stable and continuous approach, with a minimum cash dividend of 10% of the distributable profits in profitable years [107]. - The company has not made any cash dividends in the last three years, with total cash dividends amounting to 0 CNY [112]. - The company’s cash dividend policy requires that cash dividends should not exceed 30% of the average annual distributable profits over the last three years [107]. - The company’s board of directors is responsible for proposing profit distribution plans based on profitability and funding needs [108]. - The company’s profit distribution plan must be approved by the shareholders' meeting, ensuring communication with minority shareholders [110]. - The company’s cash dividend policy is aligned with its articles of association and has been deemed compliant by independent directors [111]. - The company reported a net profit available for distribution to ordinary shareholders of 55,867,920.60 in 2020, with a cash dividend payout ratio of 0.00% [115]. Regulatory and Compliance Issues - The implementation of multiple pharmaceutical policy reforms has increased operational risks, affecting production costs and human resource expenditures [7]. - The company is closely monitoring industry developments and continuously improving its management levels to mitigate risks from policy changes [10]. - Regulatory changes in the pharmaceutical industry may increase operational costs and introduce uncertainties, impacting production and sales [99]. - The company has not experienced major product quality incidents but acknowledges potential future risks related to raw material quality and handling [101]. - The company has committed to ensuring that its financial personnel do not hold concurrent positions in other controlled enterprises [127]. - The company emphasizes compliance with relevant laws and regulations in all transactions and operations [130]. Legal Matters - The company is involved in multiple legal disputes, including a case with China Bank regarding a loan of 11,953,942.74 CNY and associated interest [169]. - The company has been ordered to pay 20,999,000 CNY in principal and 262,879.17 CNY in interest to China Bank, with a ten-day deadline for repayment following the judgment [170]. - The company has a pending claim against Jiangsu Zhenfa New Energy Material Development Co., Ltd. for 46,171,177.33 CNY in goods payment and 2,750,731.25 CNY in overdue interest [167]. - The company has successfully resolved a labor dispute with a total compensation of ¥250,000 to the claimant, which was paid in full by August 20, 2020 [173]. - The company has been proactive in legal matters, applying for enforcement of court judgments to recover outstanding payments from various defendants [172]. Research and Development - Research and development expenses amounted to ¥11.34 million, down 38.95% year-on-year [62]. - The company aims to enhance its product offerings through ongoing research and development initiatives [124]. - The company emphasizes continuous product quality improvement and has implemented innovative packaging solutions, such as including Braille on product labels [57]. - The company has applied for 4 new trademarks and 5 new utility model patents during the reporting period [64]. Operational Changes - The company has undergone changes in its consolidation scope, including the disposal of subsidiaries and the cancellation of its photovoltaic business [78][79]. - The company has transitioned its main business focus from the photovoltaic industry to the pharmaceutical sector, resulting in a complete cessation of photovoltaic product sales [73]. - The company has successfully executed a judicial sale of real estate assets valued at 8,810,000 CNY, covering the debts owed [169]. - The company completed the sale of 100% equity in Youchuang Optoelectronics for 544.46 million yuan, with all payments received by April 2020 [196].

浙江向日葵大健康科技股份有限公司 2020 年第三季度报告全文 浙江向日葵大健康科技股份有限公司 2020 年第三季度报告 2020 年 10 月 1 浙江向日葵大健康科技股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曹阳、主管会计工作负责人潘卫标及会计机构负责人(会计主管 人员)吴丹琳声明：保证季度报告中财务报表的真实、准确、完整。 2 浙江向日葵大健康科技股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部 | 278,886.84 | | | 分） | | | | 计入当期损益的政府补助（与企业业务密切相关，按照国家 | 2,524,573.96 | | | ...

浙江向日葵大健康科技股份有限公司 2020 年半年度报告全文 浙江向日葵大健康科技股份有限公司 2020 年半年度报告 2020 年 08 月 1 浙江向日葵大健康科技股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人曹阳、主管会计工作负责人潘卫标及会计机构负责人(会计主管 人员)吴丹琳声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及的公司未来发展战略、经营计划等前瞻性陈述，不构成公司对 投资者的实质承诺，敬请投资者注意投资风险。 1、新冠疫情影响风险 受 2020 年初以来的新型冠状病毒感染肺炎疫情影响，公司春节后复工时间 较往年延迟，同时产业链上下游复工进度不一致，叠加疫情持续影响物流运输、 采购、销售等环节，对公司生产销售造成不利影响。随着国内疫情控制形势好 转、各行业陆续复工复产以及国家采取一系列促进经济政策，都将助推国内经 济得到较快恢复，公司在国内市场的 ...